Researchers map immune response to COVID-19

Researchers map immune response to COVID-19

Australian researchers announced they have mapped the immune responses from one of country’s first coronavirus patients, Reuters reported.


In the same way as it is a flu


Researchers at Australia’s Peter Doherty Institute for Infection and Immunity said they discovered that people’s immune systems respond to coronavirus in the same way it typically fights flu. 


The team examined the blood results from an unidentified woman in her 40s. 


Researchers did not name the patient, but said she was an Australian citizen who was evacuated out of Wuhan, the epicentre of the coronavirus outbreak in China.


As researchers monitored the Australian patient’s immune response, they were able to accurately predict when she would recover.


Understand why some patients recover from COVID-19


The findings help scientists understand why some patients recover while others develop more serious respiratory problems, the researchers said.

People can use our methods to understand the immune responses in larger COVID-19 cohorts, and also understand what’s lacking in those who have fatal outcomes,” said Katherine Kedzierska, professor of microbiology and immunology at the University of Melbourne, which took part in the research. COVID-19 is the disease caused by the coronavirus.

World leading development


Health Minister Greg Hunt described the development as “world leading” and a major development in research on the disease.

 It’s about fast-tracking a vaccine by identifying which candidates are most likely to be successful,” Hunt told reporters. “It’s also about fast-tracking potential therapies and treatments for patients who already have coronavirus.”


Costs for vaccines could run as high as $800 million

A dozen drugmakers around the world are working on vaccines or antiviral and other treatments for the fast-spreading contagion.


But investment costs for vaccines could run as high as $800 million. Even if the process is accelerated, it will likely take more than a year until approval, according to executives from companies involved in the effort.